Boosted protease inhibitor monotherapy. What have we learnt after seven years of research?

AIDS Reviews

Volumn 12, Issue 3, 2010, Pages 127-134

  Pulido, Federico ^a,b   Matarranz, Mariano ^a   Rodríguez Rivera, Violeta ^a   Fiorante, Silvana ^a,c   Hernando, Asunción ^a,c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSIDAD EUROPEA DE MADRID   (Spain)

Author keywords

Antiretroviral therapy; Monotherapy; Protease inhibitors; Simplification

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; DARUNAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; PYRIMIDINONE DERIVATIVE; RITONAVIR; SULFONAMIDE;

DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MONOTHERAPY; PATIENT COMPLIANCE; REVIEW; TREATMENT FAILURE; TREATMENT INDICATION; VIRUS LOAD; VIRUS REPLICATION; DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PYRIMIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RITONAVIR; SULFONAMIDES;

EID: 78049504333     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [accessed April 27, 2010].
2. Panel de expertos de Gesida y Plan Nacional sobre el Sida. Recomendaciones de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antiretroviral en adultos infectados por el virus de la inmunodeficiencia humana (update February 2009). Enferm Infecc Microbiol Clin. 2009;27:222-35.
3. Havlir D, Marschner I, Hirsch M, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998;339:1261-8.
4. Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomised trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. N Engl J Med 1998;339:1269-76.
5. Reijers M, Weverling G, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet. 1998;352:185-90.
6. Kahlert C, Hupfer M, Wagels T, et al. Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection. AIDS 2004;18:955-7.
7. Gathe J, Washington M, Mayberry C, et al. IMANI-1 TC3WP Single drug HAART-proof of concept study. Pilot study of the safety and efficacy of Kaletra (LPV/r) as single drug HAART in HIV + ARV-naive patients: interim analysis of subjects completing final 48 week data. Program and abstracts of the XV International AIDS Conference; July, 2004; Bangkok, Thailand. [Abstract MoOrB1057].
8. Arribas J, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression. 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 2005;40:280-7.
9. Ruane P, Luber A, Gaultier C, et al. Maintenance therapy using lopinavir/ritonavir (LPV/r) alone with well-controlled HIV Infection. Program and abstracts of the XV International Conference on AIDS; July, 2004, Bangkok, Thailand. [Abstract TuPeB4577].
10. Pierone G, Mieras J, Bulgin-Coleman D, et al. A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy. HIV Clin Trials. 2006;7:237-45. (Pubitemid 44963807)
11. Campo R, Lalanne R, Tanner T, et al. Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 2005;19:447-9.
12. Gathe J, Yeh R, Mayberry C, et al. Single-agent therapy with lopinavir/ritonavir suppresses plasma HIV-1 viral replication in HIV-1 naive subjects: IMANI-2 48- week results. Program and abstracts of the 4th IAS Conference; July 2007; Sydney, Australia. [Abstract WEPEB034].
13. Delfraissy J, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS. 2008;22:385-93.
14. Pozniak A, Gallant J, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-40. (Pubitemid 44885619)
15. Ghosn J, Flandre P, Cohen-Codar I, et al. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. HIV Med 2010;11:137-42.
16. Cameron D, da Silva B, Arribas J, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008;198:234-40. (Pubitemid 352019289)
17. Riddler S, Haubrich R, DiRienzo A, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-106.
18. Haubrich R, Riddler S, DiRienzo A, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23:1109-18.
19. Pulido F, Arribas J, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008;22:F1-9.
20. Arribas J, Delgado R, Arranz A, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr. 2009;51:147-52.
21. Arribas J, Pulido F, Delgado R, et al. Monoterapia con Lopinavir-ritonavir (LPV/r) para el mantenimiento de la supresión viral: análisis combinado de tres cohortes diferentes incluidas en dos ensayos clínicos. I Congreso Nacional de Gesida, October 2009, Madrid, Spain.
22. Enf Infecc Microbiol Clin. 2009;27:34 [abstract PO69].
23. Nunes E, Santini de Oliveira M, Merçon M, et al. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). HIV Clin Trials. 2009;10:368-74.
24. Cahn P, Andrade-Villanueva J, Sierra-Madero J, et al. Efficacy and safety of lopinavir/ritonavir monotherapy vs. standard of care consisting of a protease inhibitor and two NRTIs in adults with HIV-1. Program and abstracts of the 12th European AIDS Conference; November 2009; Cologne, Germany. [Abstract PS4/3].
25. Gutmann C, Opravil M, Fux C, et al. Unexpectedly high failure rate in LPV/r monotherapy arm, involving CNS, and association with low nadir CD4 count in the MOST study. Program and abstracts of the 16th CROI; February 2009, Montreal, Canada. [Abstract L189].
26. Gathe J, Mayberry C, Miguel B, et al. Once-daily single-agent therapy with LPV(r) in subjects virologically suppressed on twice-daily LPV(r) single-agent therapy - IMANI III 48-week final results. Program and abstracts of the 12th European AIDS Conference; November 2009, Cologne, Germany [Abstract PS4/5].
27. Arribas J, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010;24:223-30.
28. Katlama C, Valantin M, Algarte-Genin M, et al. A randomized multicenter study to compare the efficacy of a monotherapy of darunavir to a triple therapy with 2 nucleosides analogues combined to darunavir/r in HIV infected patients with full viral suppression. Program and abstracts of the 5th Conference on HIV Pathogenesis, Treatment and Prevention (IAS); July 2009, Cape Town, South Africa. [Abstract WELBB102].
29. Valantin M, Flandre P, Koita S, et al. Fat tissue distribution changes in HIV-infected patients with viral suppression treated with darunavir/ritonavir (DRV/r) monotherapy versus 2 NRTIs + DRV/r in the MONOI-ANRS 136 randomized trial: Results at 48 weeks 17th CROI, February 2010, San Francisco, CA. [Abstract 721].
30. Wilkin T, McKinnon J, DiRienzo A, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis. 2009;199:866-71.
31. Vernazza P, Daneel S, Schiffer V, et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS. 2007;21:1309-15.
32. Karlström O, Josephson F, Sönnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy J Acquir Immune Defic Syndr. 2007;44:417-22.
33. Pulido F, Serrano O, Rivero A, et al. Atazanavir/ritonavir monotherapy for maintenance of virologic suppression. 48 week primary analysis of the 96 week multicenter, open-label, single-arm, pilot OREY Study. Program and abstracts of the 12th European AIDS Conference; November 2009; Cologne, Germany [Abstract PS4/4].
34. Ribaudo H, Kuritzkes D, Schackman B, et al. Design issues in initial HIV-treatment trials: focus on ACTG A5095 Antivir Ther. 2006;11:751-60.
35. McKinnon J, Arribas J, Pulido F, et al. The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. AIDS. 2006;20:2331-5.
36. Letendre S, Ellis R, Deutsch R, et al. Correlates of time-to-loss-of- viral-response in CSF and plasma in the CHARTER cohort. 17th CROI, February 2010, San Francisco, CA. [Abstract 430].
37. Yeh R, Letendre S, Novak I, et al. Single-agent therapy with lopinavir/ritonavir controls HIV-1 viral replication in the central nervous system. 14th CROI, 2007; Los Angeles, CA. [Abstract 381].
38. Pulido F, Delgado R, Pérez-Valero I, et al. Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression. J Antimicrob Chemother. 2008;61:1359-61. (Pubitemid 351753608)
39. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50:773-8.
40. Battegay M, Bucher H. Antiretroviral monotherapy: should we abandon the principles of successful antiretroviral therapy? AIDS. 2010;24:1057-9.
41. European AIDS Clinical Society. Clinical management and treatment of HIV infected adults in Europe. Version 5 November 2009. Available at http://www.europeanaidsclinicalsociety.org/guidelinespdf/1-Treatment-of-HIV- Infected-Adults.pdf [accessed April 27, 2010].
42. Escobar I, Pulido F, Pérez E, et al. Pharmacoeconomic analysis of a maintenance strategy with lopinavir/ritonavir monotherapy in HIV-infected patients. Enferm Infecc Microbiol Clin. 2006;24:490-4. (Pubitemid 44745487)